Cutaneous metastasis to the face from colon adenocarcinoma. Case report

BACKGROUND: Facial skin metastases from colorectal cancer are extremely rare and appear several years after resection of the primary tumour. They are an important finding, often being the first sign of metastasis from a previously treated colon cancer. CASE PRESENTATION: We describe a case of a 69 year old patient with cutaneous metastasis to the chin from a previously treated adenocarcinoma of the colon. The patient presented with dyspnoea, pleuritic pain and loss of weight. A chest x-ray revealed a right upper lobe mass of the lung which on subsequent surgical exploration proved to be metastatic from colorectal adenocarcinoma resected three years ago. During the postoperative course, a nodule was noted on the chin and excision biopsy revealed it was also a metastasis from the initial colorectal cancer. Palliative chemoradiotherapy was administered and the patient survived 8 months. CONCLUSION: High index of suspicion is necessary for the early detection of facial cutaneous metastases from colorectal cancer. The aim is to start treatment as soon as possible before widespread visceral metastases occur. Cutaneous metastases from colorectal cancer carry a better prognosis in comparison to those of other epithelial tumours

Polymerisable surfactants for polymethacrylates using catalytic chain transfer polymerisation (CCTP) combined with sulfur free-RAFT in emulsion polymerisation

Statistical copolymers of methacrylic acid and methyl methacrylate were synthesised via free radical catalytic chain transfer polymerisation (CCTP) in emulsion to form a hydrophilic emulsifier/surfactant. The vinyl-terminated oligomers were in turn utilised as chain transfer agents, with no further purification, for the formation of diblock copolymers with butyl and methyl methacrylate which constitutes the emulsifier via sulfur-free reversible addition–fragmentation chain transfer polymerisation (SF-RAFT). In turn these polymers were solubilized with various concentrations of ammonium hydroxide and utilised in the surfactant-free emulsion polymerization of butyl methacrylate using persulfate initiators, which also stabilized the polymer particles with observed no coagulation, with solid contents as high as 40%

A two-fluid single-column model of the dry, shear-free, convective boundary layer

This is the final version. Available on open access from Wiley via the DOI in this record.A single-column model of the dry, shear-free, convective boundary layer is presented in which nonlocal transports by coherent structures such as thermals are represented by the partitioning of the fluid into two components, updraft and environment, each with a full set of prognostic dynamical equations. Local eddy diffusive transport and entrainment and detrainment are represented by parameterizations similar to those used in Eddy Diffusivity Mass Flux schemes. The inclusion of vertical diffusion of the vertical velocity is shown to be important for suppressing an instability inherent in the governing equations. A semi-implicit semi-Lagrangian numerical solution method is presented and shown to be stable for large acoustic and diffusive Courant numbers, though it becomes unstable for large advective Courant numbers. The solutions are able to capture key physical features of the dry convective boundary layer. Some of the numerical challenges posed by sharp features in the solution are discussed, and areas where the model could be improved are highlighted.Natural Environment Research Council (NERC

Zn doped iron oxide nanoparticles with high magnetization and photothermal efficiency for cancer treatment

Magnetic nanoparticles (NPs) are powerful agents to induce hyperthermia in tumours upon the application of an alternating magnetic field or an infrared laser. Dopants have been investigated to alter different properties of materials. Herein, the effect of zinc doping into iron oxide NPs on their magnetic properties and structural characteristics has been investigated in-depth. A high temperature reaction with autogenous pressure was used to prepare iron oxide and zinc ferrite NPs of same size and morphology for direct comparison. Pressure was key in obtaining high quality nanocrystals with reduced lattice strain (27% less) and enhanced magnetic properties. Zn_{0.4}Fe_{2.6}O_{4} NPs. with small size of 10.2 ± 2.5 nm and very high saturation magnetisation of 142 ± 9 emu g_{Fe+Zn}^{−1} were obtained. Aqueous dispersion of the NPs showed long term magnetic (up to 24 months) and colloidal stability (at least 6 d) at physiologically mimicking conditions. The samples had been kept in the fridge and had been stable for four years. The biocompatibility of Zn_{0.4}Fe_{2.6}O_{4} NPs was next evaluated by metabolic activity, membrane integrity and clonogenic assays, which show an equivalence to that of iron oxide NPs. Zinc doping decreased the bandgap of the material by 22% making it a more efficient photothermal agent than iron oxide-based ones. Semiconductor photo-hyperthermia was shown to outperform magneto-hyperthermia in cancer cells, reaching the same temperature 17 times faster whilst using 20 times less material (20 mg_{Fe+Zn} ml^{−1}vs. 1 mg_{Fe+Zn} ml^{−1}). Magnetothermal conversion was minimally hindered in the cellular confinement whilst photothermal efficiency remained unchanged. Photothermia treatment alone achieved 100% cell death after 10 min of treatment compared to only 30% cell death achieved with magnetothermia at clinically relevant settings for each at their best performing concentration. Altogether, these results suggest that the biocompatible and superparamagnetic zinc ferrite NPs could be a next biomaterial of choice for photo-hyperthermia, which could outperform current iron oxide NPs for magnetic hyperthermia

Functional pH-responsive polymers containing dynamic enaminone linkages for the release of active organic amines

Dynamic covalent bonds have attracted considerable attention for the development of pH-responsive polymers, however, studies using acid-cleavable enaminone linkages as a means of controlled release are limited. Herein, we report pH-sensitive benzocaine-modified poly(ethylene glycol) monomethyl ether-block-poly[2-(acetoacetoxy)ethyl methacrylate] (mPEGx-b-pAEMAy)/BNZ nanoparticles (NPs) for the aqueous controlled release of benzocaine through enaminone bond cleavage. The system is based on the commercially available monomer 2-(acetoacetoxy)ethyl methacrylate (AEMA) which contains free pendant β-ketoester functionality. Well-defined poly[2-(acetoacetoxy)ethyl methacrylate] (pAEMA) homopolymers and poly[(ethylene glycol) monomethyl ether]-block-poly[2-(acetoacetoxy)ethyl methacrylate] (mPEGx-b-pAEMAy) amphiphilic block copolymers were prepared by photoinduced Cu(II)-mediated RDRP to investigate their modification with propylamine (a model amine) and benzocaine (a primary amine containing API) through an enaminone bond. Block copolymers were prepared via two poly(ethylene glycol) monomethyl ether-2-bromo-2-phenylacetate (mPEGx-BPA, x = 43 or 113) macroinitiators synthesised by esterification which acted as the hydrophilic coronas of the ensuing NPs. The self-assembly of both mPEGx-b-pAEMAy and (mPEGx-b-pAEMAy)/BNZ was assessed in water by the direct dilution approach forming spherical NPs as characterised by dynamic light scattering (DLS) and dry-state transmission electron microscopy (TEM). Finally, the in vitro controlled release of benzocaine from mPEGx-b-pAEMAy/BNZ NPs was examined at different pH environments demonstrating faster release kinetics at lower pH with potential utility in applications with relevant chemical environments

Angiomyofibroblastoma of the spermatic cord: a case report

<p>Abstract</p> <p>Introduction</p> <p>Angiomyofibroblastoma is a benign soft tissue tumor with tendency to arise in the vulva.</p> <p>Case presentation</p> <p>We report a 36-year-old Greek Caucasian man presenting with a left inguinal painless mass. This is the second case of angiomyofibroblastoma of the spermatic cord. At operation, a 4.5 cm well-circumscribed solid tumor was found adherent to the spermatic cord. The tumor consisted of spindle-shaped cells proliferating in short fascicles between numerous medium-sized blood vessels with thin and hyalinized walls. Neoplastic cells had eosinophilic cytoplasm with neither mitotic figures nor nuclear atypia. The stroma included abundant mast cells and few mature lypocytes. Immunostaining showed positivity for vimentin, CD34, desmin and smooth muscle actin. Our patient was treated by simple excision and was followed up for five years with clinical examination and ultrasonography, revealing no evidence of local recurrence or metastasis.</p> <p>Conclusion</p> <p>This unusual neoplasm should be distinguished from aggressive angiomyxoma and other myxoid malignant tumors with widespread metastatic potential.</p

Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group

BACKGROUND: Surgery can cure a significant percentage of ovarian carcinoma confined to the pelvis. Nevertheless, there is still a 10–50% recurrence rate. We administered paclitaxel/carboplatin as adjuvant treatment in early-stage ovarian carcinoma. METHODS: Patients with stages Ia or Ib, Grade 2 or 3 and Ic to IIb (any grade) were included. Patients were treated with 4 cycles of Paclitaxel 175 mg/m(2 )and Carboplatin [area under the curve (AUC) 6 (Calvert Formula)] every 3 weeks. RESULTS: Sixty-nine patients with no residual disease following cytoreductive surgery and minimal or modified surgical staging were included in this analysis. Grade 3 or 4 neutropenia occured in 29.9% of patients, while neutropenic fever was reported in 4.5%. Neurotoxicity (all Grade 1 or 2) was reported in 50% of cases. Median follow-up was 62 months. 5-year overall survival (OS) and relapse-free survival (RFS) were: 87% (95% confidence intervals [CI]: 78–96) and 79% (95% CI: 69–89), respectively. Significantly fewer patients with stages Ic-IIb and tumor grade 2 or 3 achieved a 5-year RFS than patients with only one of these two factors (73% vs 92%, p = 0.03). CONCLUSION: Paclitaxel/Carboplatin chemotherapy is a safe and effective adjuvant treatment in early-stage ovarian carcinoma. Patients with stages Ic-IIb and tumor grade 2 or 3 may benefit from more extensive treatment